Circulatory neutrophil chemokines in statin-treated diabetic patients

Authors

• Assim A. Alfadda, Department of Internal Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia.
• Mohammed A. Alzoghaibi, Department of Internal Medicine, College of Medicine and King Khalid University Hospital, King Saud University, PO Box 2925, Riyadh 11461, Kingdom of Saudi Arabia. Tel. + 966 (1) 4671497. Fax. +966 (1) 4671518. E-mail: aalfadda{at}ksu.edu.sa

Abstract

OBJECTIVE: To assess the effect of statins on the circulatory levels of neutrophil chemokines, namely, granulocyte chemotactic protein-2 GCP-2, growth regulated oncogene-alpha GRO-a and epithelial-cell-derived neutrophil-activating peptide-78 ENA-78 in patients with diabetes. METHODS: We studied 91 diabetic patients 46 were statin-treated and 45 were not and 28 healthy subjects. We measured the levels of GCP-2, GRO-a, and ENA-78 in the serum for the 3 groups using an enzyme linked immunosorbent assay. This cross-sectional study was conducted at King Khalid University Hospital KKUH, Riyadh, Kingdom of Saudi Arabia, from January 2006 to July 2007. RESULTS: Circulating levels of GCP-2, ENA-78, and not GRO-a, were significantly higher in diabetic patients as compared to healthy subjects p<0.05. Statins dropped the levels of both GCP-2 and GRO-a. The ENA-78 levels were not affected by statin therapy. There was no correlation between the levels of these chemokines with the body mass index and glycemia in the population studied. CONCLUSION: Diabetes is associated with an elevation of GCP-2 and ENA-78, and not GRO-a. Statins have a significant role in reducing the level of GCP-2.

Article Type

Research Article

First Page

584

Last Page

588

Recommended Citation

Alfadda, Assim A. and Alzoghaibi, Mohammed A. (2008) "Circulatory neutrophil chemokines in statin-treated diabetic patients," Saudi Medical Journal: Vol. 29: Iss. 4, Article 19.
DOI: https://doi.org/10.15537/1658-3175.4301